In single IRB arrangements, the reviewing IRB (whether at UCLA or any other institution) is responsible for considering local context, including state laws and institutional requirements. This typically requires targeted changes to recruitment and consent documents so that participants have correct information.

Please use this checklist when updating consent forms for review by a non-UCLA IRB. Also consider whether these changes are applicable to assent forms, information sheets and recruitment materials.

| ☐ Heading: Add “University of California, Los Angeles” |
| ☐ Introduction: Name the UCLA Principal Investigator and his/her department in the introductory paragraph. For example, “Maureen Kwan, MD and her associates in the Department of Pediatrics at UCLA and …. [investigator at other named site] are conducting a research study.” UCLA discourages listing all study team members in the consent form. |
| ☐ Procedures: State where at UCLA procedures will take place, if appropriate. |
| ☐ Contact for Study Questions and Injury: Provide the local UCLA PI’s contact information. |
| ☐ Contact for Questions about Rights: Unless the reviewing IRB prefers to include its own contact information or another central contact, insert the following:

“If you have questions about your rights as a research subject, or you have concerns or suggestions and you want to talk to someone other than the researchers, you may contact the UCLA OHRPP by phone: (310) 206-2040; by email: participants@research.ucla.edu or by mail: Box 951406, Los Angeles, CA 90095-1406.” |
| ☐ Disclosures: Disclose financial or other conflicts of interest (whether on the part of team members or of UCLA) in the appropriate section. See UCLA OHRPP Guidance. |
| ☐ HIPAA Authorization: If Protected Health Information will be accessed, used, created or disclosed from UCLA medical records, use and refer to the University of California Permission to Use PHI for Research Forms. For reasons of state law, do not incorporate HIPAA language into the consent form but use the following statement instead: “You will be asked to sign a separate form authorizing access, use, creation, or disclosure of health information about you.”

NOTE: The consent form should still describe confidentiality of research data. |
| ☐ Injury: You must use UCLA’s standard language (unless the other institution is a UC) when injury information is needed. See UCLA OHRPP Guidance for more details.

“It is important that you promptly tell the researchers if you believe that you have been injured because of taking part in this study. You can tell the researcher in person or call him/her at the number(s) listed above.

If you are injured as a result of being in this study, UCLA will provide necessary medical treatment. The costs of the treatment may be covered by the University of California or the study sponsor [sponsor name], or billed to you or your insurer just like other medical costs, depending on a number of factors. The University and the study sponsor do not normally provide any other form of compensation for injury. For more information about this, you may call the UCLA Office of the Human Research Protection Program at 310-206-2040 or email participants@research.ucla.edu.” |
| ☐ Commercial Value of Specimens: | Include the following statement if your research involves collection of biospecimens (you may remove the references to re-use or sharing of specimens/information if not applicable):

“Biospecimens (such as blood, tissue, or saliva) collected from you for this study and/or information obtained from your biospecimens may be used in this research or other research, and shared with other organizations. You will not share in any commercial value or profit derived from the use of your biospecimens and/or information obtained from them.” |
| ☐ Costs: | If the study requires services or resources owned/rented/operated or provided by the UCLA Health System (e.g. clinic and/or hospital visit(s), CTRC, professional medical services, clinical treatment, diagnostics, labs, medical supplies, etc.), then insert the Coverage Analysis statement appropriate to how procedures will be billed:

**If Billed All to Research:** “The study will pay for the cost of supplying and administering the study drug/device, and all required study items and services as described in this consent form.”

**If Billed to a Split of Research and Insurance/Subject:** “The study will pay for research-related items and/or services that are provided only because you are participating in the study. These research-related items and/or services are explained in other areas of this consent form.

You or your health plan may be responsible to pay for all the types of items listed below:

- Items and services that would have been provided to you even if you were not in the study
- Health care given during the study as part of your regular care
- Items or services needed to give you study drugs or devices
- Monitoring for side effects or other problems
- Deductibles or co-pays for these items and/or services”

**All Standard of Care:** “There will be no additional cost to you or your health plan as a result of your participation in this study. Items and services described in this consent form would have occurred regardless of your participation in this study or, if research-related, will be provided to you at no cost.”

**NOTE:** Contact coverageanalysis@mednet.ucla.edu with questions about the above. |
| ☐ Bill of Rights: | If the study poses a real or foreseeable risk of biomedical harm and takes place in California, includes language such as the following: “You will be given a copy of this consent form and the Research Participant’s Bill of Rights to keep.” Give the participant a copy in a language in which he or she is fluent (see [here](#)). **NOTE:** UC does not require the Bill of Rights document to be signed and does not include the Bill in the body of the consent form. |
| ☐ Ancillary Reviews: | If any local ancillary reviews result in changes to the consent form, you must convey those changes to the reviewing IRB. For example, the Medical Radiation Safety Committee requires the use of specific language to describe the risks of radiation procedures. |